Search
Filter Results
Displaying 581–590 of 724 for “Visions 2020”
-
Jan 13, 2021
ProQR Completes Enrollment in Phase 2/3 Clinical Trial of RNA Therapy for LCA10
Company also announced progress in enrollment for Phase 1 / 2 clinical trials for emerging USH2A and RHO RNA therapies.
-
Jan 7, 2021
REGENXBIO’s Wet AMD Gene Therapy Moving into Phase 3 Trials
In a Phase ½ clinical trial, the emerging treatment reduced the burden of regular anti-VEGF injections
-
A friendly year end reminder to make sure you are aware of a popular end-of-year giving opportunity. In 2020, organizations like the Foundation Fighting Blindness have seen a huge uptick in gifts made through appreciated stock/securities. This is a great way to avoid capital gains taxes AND support a mission that’s important to you.
-
Dec 10, 2020
Mr. Ginsberg brings twenty-five years of rare disease corporate development, finance, strategy, and investment leadership experience.
-
Nov 19, 2020
Foundation Fighting Blindness Launches ShopFightingBlindness.org
This official store offers branded apparel and merchandise designed to spread awareness and raise funds for the Foundation’s mission.
-
Sep 25, 2020
Many users find that using an external keyboard with keyboard shortcuts for Microsoft Teams on Windows helps them work more efficiently. For users with mobility or vision disabilities, keyboard shortcuts can be easier than using the touchscreen and are an essential alternative to using a mouse.
-
An Eye on Education Video Series
Learn all about inherited retinal diseases and related science topics by watching (or listening to) the Foundation’s educational video series developed for patients, families, and other lay audiences.
-
Aug 5, 2020
Foundation Fighting Blindness and the Retinal Degeneration Fund
In 2018, the Foundation Fighting Blindness launched a venture philanthropy investment arm called the Retinal Degeneration (RD) Fund to help companies and researchers advance promising treatments for inherited retinal diseases into and through early-stage human studies. Currently, the RD Fund has allocated about 75% of its $72 million fund to eight investments.
-
Bronze Partner - Janssen Pharmaceutical Companies
Bronze Partner - Janssen Pharmaceutical Companies
-
Jul 7, 2020
Biogen Entering into Licensing Agreement with Mass Eye and Ear to Develop PRPF31 Gene Therapy
The goal of the partnership is to advance a PRPF31 gene therapy into a clinical trial